立体定向放射治疗早期小细胞肺癌研究进展

doi:10.3760/cma.j.cn113030-20200825-00437

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Small cell lung cancer (SCLC) is a poorly differentiated, rapidly aggressive and highly chemoradio-sensitive malignancy. Recent research finds that stereotactic body radiation therapy (SBRT) is well tolerated in the treatment of early-stage SCLC with excellent locoregional control rates. This paradigm could offer comparable overall survival and cancer-specific survival with surgery or conventional concurrent chemoradiotherapy. Presently, SBRT has become one of the standard treatment options for patients with stage I-IIA SCLC. Due to the enlightened role of SBRT in the treatment of SCLC, this review aims to discuss the clinical research to date in the application status, clinical value and developing tendency of SBRT in the treatment of patients with early-stage SCLC.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Xiao Xi
	Wang Jianyang
	Bi Nan

Key words： Small cell lung carcinoma early-stage Stereotactic body radiation therapy Research progress

Received: 25 August 2020

Fund:; Fund programs: Natural Science Foundation of China(81602168); The National Key Research and Development Program of China(2016YFC0904600); CAMS Innovation Fund for Medical Sciences(2017-I2M-2-005)

Corresponding Authors: Wang Jianyang, Email: pkucell@163.com

Cite this article:

Xiao Xi,Wang Jianyang,Bi Nan. Research progress on the application of stereotactic body radiation therapy in the treatment of early-stage small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(7): 660-665.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200825-00437 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2022/V31/I7/660

[1] Lax I, Blomgren H, Näslund I, et al.Stereotactic radiotherapy of malignancies in the abdomen. methodological aspects[J]. Acta Oncol, 1994, 33(6):677-683. DOI: 10.3109/02841869409121782.
[2] Blomgren H, Lax I, Näslund I, et al.Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. clinical experience of the first thirty-one patients[J]. Acta Oncol, 1995, 34(6):861-870. DOI: 10.3109/02841869509127197.
[3] Nagata Y.Introduction and history of stereotactic body radiation therapy (SBRT)[M].// Nagata Y, editor. Stereotactic Body Radiation Therapy: Principles And Practices. Tokyo: Springer Japan, 2015: 3-8. DOI: 10.1007/978-4-431- 54883-6_1.
[4] Timmerman R, Paulus R, Galvin J, et al.Stereotactic body radiation therapy for inoperable early stage lung cancer[J]. JAMA, 2010, 303(11):1070-1076. DOI: 10.1001/jama.2010.261.
[5] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30. DOI: 10.3322/caac.21442.
[6] Badzio A, Kurowski K, Karnicka-Mlodkowska H, et al.A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer[J]. Eur J Cardiothorac Surg, 2004, 26(1):183-188. DOI: 10.1016/j.ejcts.2004.04.012.
[7] Brock MV, Hooker CM, Syphard JE, et al.Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: its time has come[J]. J Thorac Cardiovasc Surg, 2005, 129(1):64-72. DOI: 10.1016/j.jtcvs.2004.08.022.
[8] Weksler B, Nason KS, Shende M, et al.Surgical resection should be considered for stage I and II small cell carcinoma of the lung[J]. Ann Thorac Surg, 2012, 94(3):889-893. DOI: 10.1016/j.athoracsur.2012.01.015.
[9] Wakeam E, Varghese TK, Leighl NB, et al.Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer[J]. Lung Cancer, 2017, 109:117-123. DOI: 10.1016/j.lungcan.2017.05.004.
[10] National Comprehensive Cancer Network. Small cell lung cancer[S/OL].Version 2. [2019-08-05].https://www.nccn.org/
[11] Savage T, Guha C: Radio-immunology of ablative radiation[M].// Trifiletti DM, Chao ST, Sahgal A, et al, editor. Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy: A Comprehensive Guide. Cham: Springer International Publishing, 2019: 15-29. DOI: 10.1007/978-3-030-16924- 4_2.
[12] Michael PH, Adly Y, Steven G, et al.The cellular signaling response to radiation[M].// Brian D, Kavanagh MD, Robert D, et al, editor. Stereotactic Body Radiation Therapy. Virginia: Lippincott Williams and Wilkins, 2005: 15-18. DOI: 10.1016/j.ijrobp.2005.05.065.
[13] Shibamoto Y, Miyakawa A, Iwata H, et al.Radiobiology of SBRT[M].// Nagata Y, editor. Stereotactic Body Radiation Therapy: Principles and Practices. Tokyo: Springer Japan, 2015: 11-25. DOI: 10.1007/978-4-431-54883-6_2.
[14] Brown JM, Carlson DJ, Brenner DJ.The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?[J]. Int J Radiat Oncol Biol Phys, 2014, 88(2):254-262. DOI: 10.1016/j.ijrobp.2013.07.022.
[15] Park HJ, Griffin RJ, Hui S, et al.Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)[J]. Radiat Res, 2012, 177(3):311-327. DOI: 10.1667/rr2773.1.
[16] Garcia-Barros M, Paris F, Cordon-Cardo C, et al.Tumor response to radiotherapy regulated by endothelial cell apoptosis[J]. Science, 2003, 300(5622):1155-1159. DOI: 10.1126/science.1082504.
[17] Lee Y, Auh SL, Wang Y, et al.Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment[J]. Blood, 2009, 114(3):589-595. DOI: 10.1182/blood-2009-02-206870.
[18] Filatenkov A, Baker J, Mueller AM, et al.Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions[J]. Clin Cancer Res, 2015, 21(16):3727-3739. DOI: 10.1158/1078-0432.CCR-14-2824.
[19] Dewan MZ, Galloway AE, Kawashima N, et al.Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J]. Clin Cancer Res, 2009, 15(17):5379-5388. DOI: 10.1158/1078-0432.CCR-09-0265.
[20] Shioyama Y, Nakamura K, Sasaki T, et al.Clinical results of stereotactic body radiotherapy for stage I small-cell lung cancer: a single institutional experience[J]. J Radiat Res, 2013, 54(1):108-112. DOI: 10.1093/jrr/rrs075.
[21] Videtic GM, Stephans KL, Woody NM, et al.Stereotactic body radiation therapy-based treatment model for stage I medically inoperable small cell lung cancer[J]. Pract Radiat Oncol, 2013, 3(4):301-306. DOI: 10.1016/j.prro.2012.10.003.
[22] Ly NB, Allen PK, Lin SH.Stereotactic body radiation therapy for stage I small cell lung cancer: a single institutional case series and review of the literature[J]. J Radiat Oncol, 2014, 3(3): 285-291. DOI: 10.1007/s13566-014-0146-7.
[23] Shioyama Y, Nagata Y, Komiyama T, et al.Multi-institutional retrospective study of stereotactic body radiation therapy for stage I small cell lung cancer: Japan Radiation Oncology Study Group (JROSG)[J]. Int J Radiat Oncol Biol Phys, 2015, 93(3): S101. DOI: 10.1016/j.ijrobp.2015.07.243.
[24] Verma V, Simone CB, Allen PK, et al.Multi-institutional experience of stereotactic ablative radiation therapy for stage I small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 97(2):362-371. DOI: 10.1016/j.ijrobp.2016.10.041.
[25] Verma V, Simone CB, Allen PK, et al. Outcomes of stereotactic body radiotherapy for T1-T2N0 small cell carcinoma according to addition of chemotherapy and prophylactic cranial irradiation: A multicenter analysis[J]. Clin Lung Cancer, 2017, 18(6):675-681.e1. DOI: 10.1016/j.cllc.2017.03.009.
[26] Singh R, Ansinelli H, Sharma D, et al.Clinical outcomes following stereotactic body radiation therapy (SBRT) for stage I medically inoperable small cell lung carcinoma: A multi-institutional analysis from the RSSearch patient registry[J]. Am J Clin Oncol, 2019, 42(7):602-606. DOI: 10.1097/COC.0000000000000561.
[27] Carmichael J, Degraff WG, Gamson J, et al.Radiation sensitivity of human lung cancer cell lines[J]. Eur J Cancer Clin Oncol, 1989, 25(3):527-534. DOI: 10.1016/0277-5379(89)90266-6.
[28] Verma V, Hasan S, Wegner RE, et al.Stereotactic ablative radiation therapy versus conventionally fractionated radiation therapy for stage I small cell lung cancer[J]. Radiother Oncol, 2019, 131:145-149. DOI: 10.1016/j.radonc.2018.12.006.
[29] Alongi F, Arcangeli S, De Bari B, et al.Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature[J]. Crit Rev Oncol Hematol, 2017, 112:67-71. DOI: 10.1016/j.critrevonc.2017.02.010.
[30] Li C, Xiong Y, Zhou Z, et al.Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study[J]. Med Oncol, 2014, 31(12):369. DOI: 10.1007/s12032-014-0369-x.
[31] Stahl JM, Corso CD, Verma V, et al.Trends in stereotactic body radiation therapy for stage I small cell lung cancer[J]. Lung Cancer, 2017, 103:11-16. DOI: 10.1016/j.lungcan. 2016.11.009.
[32] Shioyama Y, Onishi H, Takayama K, et al.Clinical outcomes of stereotactic body radiotherapy for patients with stage I small-cell lung cancer: analysis of a subset of the Japanese radiological society multi-institutional SBRT study group database[J]. Technol Cancer Res Treat, 2018, 17:1533033818783904. DOI: 10.1177/1533033818783904.
[33] Newman NB, Sherry AD, Byrne DW, et al.Stereotactic body radiotherapy versus conventional radiotherapy for early-stage small cell lung cancer[J]. J Radiat Oncol, 2019, 8(2):239-248. DOI: 10.1007/s13566-019-00395-x.
[34] Inoue M, Miyoshi S, Yasumitsu T, et al.Surgical results for small cell lung cancer based on the new TNM staging system. thoracic surgery study group of osaka university, osaka, japan[J]. Ann Thorac Surg, 2000, 70(5):1615-1619. DOI: 10.1016/s0003-4975(00)01401-6.
[35] Lim E, Belcher E, Yap YK, et al.The role of surgery in the treatment of limited disease small cell lung cancer: time to reevaluate[J]. J Thorac Oncol, 2008, 3(11):1267-1271. DOI: 10.1097/JTO.0b013e318189a860.
[36] Lad T, Piantadosi S, Thomas P, et al.A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy[J]. Chest, 1994, 106(6 Suppl):320S-323S. DOI: 10.1378/chest.106.6_supplement.320s.
[37] Fox W, Scadding JG.Medical research council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. ten-year follow-up[J]. Lancet, 1973, 2(7820):63-65. DOI: 10.1016/s0140-6736(73)93260-1.
[38] Yu JB, Decker RH, Detterbeck FC, et al.Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer[J]. J Thorac Oncol, 2010, 5(2):215-219. DOI: 10.1097/JTO.0b013e3181cd3208.
[39] Yang CJ, Chan DY, Shah SA, et al.Long-term survival after surgery compared with concurrent chemoradiation for node-negative small cell lung cancer[J]. Ann Surg, 2018, 268(6):1105-1112. DOI: 10.1097/SLA.0000000000002287.
[40] Schneider BJ, Saxena A, Downey RJ.Surgery for early-stage small cell lung cancer[J]. J Natl Compr Canc Netw, 2011, 9(10):1132-1139. DOI: 10.6004/jnccn.2011.0094.
[41] Liu T, Chen Z, Dang J, et al.The role of surgery in stage I to III small cell lung cancer: A systematic review and meta-analysis[J]. PLoS One, 2018, 13(12):e0210001. DOI: 10.1371/journal.pone.0210001.
[42] Barnes H, See K, Barnett S, et al. Surgery for limited-stage small-cell lung cancer[J]. Cochrane Database Syst Rev, 2017, 4(4):CD011917. DOI: 10.1002/14651858.CD011917.pub2.